it carries a substantial risk of gastric ulcer and bleeding. Cabpirin® tablets, which include low-dose ASP and vonoprazan fumarate (VON), are approved in Japan for the treatment of acid-related diseases in patients who require a low dose of ASP but are at risk of ASP-associated gastric ...
Vonoprazan fumarate (Takecab®) is a first-in-class potassium-competitive acid blocker that has been available in the market in Japan since February 2015. Vonoprazan is administered orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the ...
A novel class of potassium-competitive gastric acid blocker,vonoprazanfumarate, has been on the market in Japan since 2015. It is used as an oral medication prescribed once daily for both treatment of gastric ulcers and secondary prevention of gastric acid reflux. Vonoprazan reversibly inhibits hydro...